Cannabinoids and the gastrointestinal tract

Gut

Volumn 48, Issue 6, 2001, Pages 859-867

  Pertwee, R G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ACETYLCHOLINE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; RIMONABANT;

ACETYLCHOLINE RELEASE; DRUG DEPENDENCE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; GASTROINTESTINAL TRACT; ILEUM; INTESTINE CONTRACTION; INTESTINE MOTILITY; MOUSE; NONHUMAN; PERISTALSIS; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE; STOMACH ACID SECRETION; STOMACH EMPTYING;

ACETYLCHOLINE; ANIMALS; CANNABINOIDS; DIGESTIVE PHYSIOLOGY; DIGESTIVE SYSTEM; DRUG TOLERANCE; ELECTRIC STIMULATION; ENTERIC NERVOUS SYSTEM; GASTRIC ACID; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; GUINEA PIGS; HALLUCINOGENS; HUMANS; MICE; POLYMERASE CHAIN REACTION; RATS; RECEPTORS, DRUG;

EID: 0035010955     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.6.859     Document Type: Review

References (83)

1. 1 Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1988;36:189-261.
2. 2 receptors. Pharmacol Ther 1997;74:129-80.
3. 3 Di Marzo V, Melck D, Bisogno T, et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;21:521-8.
4. 4 Piomelli D, Beltramo M, Glasnapp S, et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 1999;96:5802-7.
5. 5 Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999;6:635-64.
6. 6 Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. Exp Opin Invest Drugs 2000;9:1553-71.
7. 7 Gill EW, Paton WDM, Pertwee RG. Preliminary experiments in the chemistry and pharmacology of cannabis. Nature 1970;228:134-6.
8. 8 Gill EW, Paton WDM. Pharmacological experiments in vitro on the active principles of cannabis. In: Joyce CRB, Curry SH, eds. The botany and chemistry of cannabis. London: Churchill, 1970:165-73.
9. 9 Rosell S, Agurell S, Martin B. Effects of cannabinoids on isolated smooth muscle preparations. In: Nahas GG, ed. Marihuana: chemistry, biochemistry, and cellular effects. New York: Springer-Verlag, 1976:397-406.
10. 8-tetrahydrocannabinol. J Pharmacol Exp Ther 1985;234:784-91.
11. 9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol 1978;56:968-75.
12. 12 Pertwee RG, Stevenson LA, Elrick DB, et al. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea pig small intestine. Br J Pharmacol 1992;105: 980-4.
13. 1 receptors in guinea pig small intestine. Br J Pharmacol 1996;118:2199-205.
14. 14 Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea pig myenteric plexus. Br J Pharmacol 1997;121:1557-66.
15. 15 Pertwee RG, Stevenson LA, Fernando SR, et al. In vitro effects of the cannabinoid, CP55,940, and of its (+)-enantiomer, CP56,667. In: Harris L, ed. Proceeding of the 54th annual scientific meeting of the college on problems of drug dependence. Rockville, Maryland: National Institute on Drug Abuse, 1993:132;374.
16. 16 Mechoulam R, Devane WA, Glaser R, Cannabinoid geometry and biological activity. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids neurobiology and neurophysiology. Boca Raton: CRC Press Inc., 1992:1-33.
17. 17 Pertwee RG, Fernando SR, Griffin G, et al. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol 1995;272: 73-8.
18. 1 receptors in human ileum. Br J Pharmacol 1998;125: 1393-5.
19. 19 Rosell S, Björkroth U, Agurell S, et al. Relation between effects of cannabinoid derivatives on the twitch response of the isolated guinea pig ileum and their psychotropic properties. In: Nahas GG, Paton WDM, eds. Marihuana: biological effects. Oxford: Pergamon Press, 1979:63-70.
20. 20 Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994;268:1612-23.
21. 1 receptors in the myenteric plexus. International Cannabinoid Research Society 2000 Symposium on the Cannabinoids. Burlington, Vermont, 2000:1.
22. 2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 1998;82:1131-49.
23. 23 Ross RA, Brockie HC, Fernando SR, et al. Comparison of cannabinoid binding sites in guinea pig forebrain and small intestine. Br J Pharmacol 1998;125:1345-51.
24. 2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997;339:53-61.
25. 25 Shire D, Carillon C, Kaghad M, et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995;270:3726-31.
26. 1 receptors. Br J Pharmacol 1998;124:1363-8.
27. 27 Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 1994; 350:240-4.
28. 2+ and cAMP. Can J Physiol Pharmacol 1998;76:340-6.
29. 6-tetrahydrocannabinol and some related cannabinoids on the guinea pig isolated ileum. Acta Physiol Scand 1975;94:142-4.
30. 30 Ward SJ, Mastriani D, Casiano F, et al. Pravadoline: profile in isolated tissue preparations. J Pharmacol Exp Ther 1990;255:1230-9.
31. 31 Pertwee RG, Browne SE, Ross TM, et al. An investigation of the involvement of GABA in certain pharmacological effects of delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 1991;40:381-5.
32. 1-tetrahydrocannabinol and cannabidiol at cholinergic junctions. Br J Pharmacol 1971;41:379-80P.
33. 33 Paton WDM, Pertwee RG, Temple D. The general pharmacology of cannabinoids. In: Paton WDM, Crown J, eds. Cannabis and its derivatives. Oxford: Oxford University Press, 1972:50-75.
34. 34 Yal WM, Reese LA. Cannabinoid receptor: inhibition of ACh release from myenteric plexus of small intestine. Gastroenterology 1999;116:G4791.
35. 33 López-Redondo F, Lees GM, Pertwee RG. Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea pig ileum. Br J Pharmacol 1997;122:330-4.
36. 30 Fernando SR. Development of in vitro smooth muscle preparations as suitable models for elucidating the mechanism of action of cannabinoids, PhD Thesis. Aberdeen: University of Aberdeen, 1998.
37. 1 ligands in the isolated guinea pig ileum. Br J Pharmacol 2000;129:984-90.
38. 38 Heinemann A, Shahbazian A, Holzer P. Cannabinoid inhibition of guinea pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999;38:1289-97.
39. 39 Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989;249:444-9.
40. 40 Izzo AA, Mascolo N, Pinto L, et al. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999; 384:37-42.
41. 1 receptors. FASEB J 2000;14:785.
42. 42 Dewey WL, Kennedy JS, Howes JF. Some autonomic, gastrointestinal and metabolic effects of two constituents of marihuana. Fed Proc 1970;29:650.
43. 43 Dewey WL, Harris LS, Kennedy JS. Some pharmacological and toxicological effects of l-trans-Δ8-and l-trans-Δ9-tetrahydrocannabinol in laboratory rodents. Arch Int Pharmacodyn 1972;196:133-45.
44. 9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J Pharm Pharmacol 1974;26:136-7.
45. 45 Chesher GB, Dahl CJ, Everingham M, et al. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol 1973;49:588-94.
46. 9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity. Psychopharmacologia 1975;43:31-6.
47. 9-tetrahydrocannabinol on intestinal motility and on the abdominal constriction response in the mouse. Psychopharmacology 1976;47:187-93.
48. 48 Calignano A, La Rana G, Makriyannis A, et al. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 1997;340:R7-8.
49. 49 Colombo G, Agabio R, Lobina C, et al. Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 1998;344:67-9.
50. 1 receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;359:65-70.
51. 51 Izzo AA, Pinto L, Borrelli F, et al. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000;129:1627-32.
52. 52 Dagirmanjian R, Boyd ES. Some pharmacological effects of two tetrahydrocannabinols. J Pharmacol Exp Ther 1962;135:25-33.
53. 9-trans-tetrahydrocannabinol on the behaviour of rats in an open-field arena. Psychopharmacologia 1971;19:388-97.
54. 9-THC on the open-field activity of the rat. Psychopharmacologia 1972;23:289-99.
55. 55 Costa B, Vailati S, Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 1999;10:327-31.
56. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999;96: 14228-33.
57. 37 Izzo AA, Mascolo N, Capasso R, et al. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch Pharmacol 1999;360:221-3.
58. 1 receptors. Eur J Pharmacol 1999;371:187-96.
59. 59 McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999;13:77-80.
60. 60 Bateman DN. Delta-9-tetrahydrocannabinol and gastric emptying. Br J Clin Pharmacol 1983;15:749-51.
61. 61 Coruzzi G, Adami M, Coppelli G, et al. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1999;360:715-18.
62. 9-tetrahydrocannabinol in rat isolated stomach. Eur J Pharmacol 1980;65:317-18.
63. 63 Nalin DR, Rhead J, Rennels M, et al. Cannabis, hypochlorhydria and cholera. Lancet 1978;2:859-62.
64. 9-tetrahydrocannabinol in the Shay rat test. Pharmacology 1978;17:173-7.
65. 65 Coutts AA, Brewster N, Ingram T, et al. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea pig small intestine. Br J Pharmacol 2000;129:645-52.
66. 66 Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 1995;270:6030-5.
67. 67 Katayama K, Ueda N, Kurahashi Y, et al. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1997;1347:212-18.
68. 68 Ueda N, Yamamoto S. Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediators 2000;61:19-28.
69. 69 Jerman JC, Brough SJ, Davis JB, et al. The anandamide transport inhibitor AM404 is an agonist at the rat vanilloid receptor (VR1). Br J Pharmacol 2000;129:73P.
70. 70 Zygmunt PM, Chuang HH, Movahed P, et al. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 2000;396: 39-42.
71. 71 Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
72. 1 antagonism and inverse agonism in guinea pig myenteric neurones. International Cannabinoid Research Society 2000 Symposium on the Cannabinoids. Burlington, Vermont, 2000:46.
73. 1 receptor agonists. Acta Pharmacologica Sinica 1999; 20:1103-8.
74. 74 Pertwee RG, Stevenson LA, Fernando SR, et al. The production of cannabinoid tolerance in preparations of mouse vas deferens and of myenteric plexus-longitudinal muscle of mouse small intestine. Br J Pharmacol 1992;107:365P.
75. 75 Pertwee R, Fernando S, Ritchie J, et al. Preliminary validation of a novel experimental model for the study of cannabinoid tolerance. International Cannabinoid Research Society 1998 Symposium on the Cannabinoids. Burlington, Vermont, 1998:127.
76. 76 Basilico L, Parolaro D, Colleoni M, et al. Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea pig ileum myenteric plexus. Eur J Pharmacol 1999;376:265-71.
77. 1 receptor antagonist SR141716 in isolated strips of human small intestine. International Cannabinoid Research Society 2000 Symposium on the Cannabinoids. Burlington, Vermont, 2000:82.
78. 78 Lichtman AH, Wiley JL, LaVecchia KL, et al. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur J Pharmacol 1998;357:139-48.
79. 79 Hine B, Friedman E, Torrelio M, et al. Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 1975;187:443-5.
80. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1976;199:375-84.
81. 81 Morrone LA, Romanelli L, Mazzanti G, et al. Hashish antagonism on the in vitro development of withdrawal contracture. Pharmacol Res 1993;27(suppl 1):63-4.
82. 82 Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, ed. Cannabinoids as therapeutic agents. Boca Raton: CRC Press Inc., 1986:1-19.
83. 83 Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol (in press).